Rapport Therapeutics, Inc. Common Stock (RAPP) — Financial statements
Income statement, balance sheet, and cash flow for Rapport Therapeutics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1↑21.2% | 0.84↑649.1% | 0.11↑646.7% | 0.02 | |
| Gross Profit | -1↓21.2% | -0.84↓649.1% | -0.11↓646.7% | -0.02 | |
| Operating Expenses | |||||
| R&D Expenses | 95↑55.6% | 61↑117.6% | 28↑207.2% | 9 | |
| General & Administrative Expenses | 30↑37.0% | 22↑170.4% | 8↑498.9% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.11 | 0.00 | |
| SG&A Expenses | 30↑37.0% | 22↑174.2% | 8↑490.7% | 1 | |
| Other Expenses | 0.00↑100.0% | -0.84 | 0.00↑100.0% | -0.13 | |
| Operating Expenses | 125↑52.2% | 82↑128.0% | 36↑248.4% | 10 | |
| Total Costs & Expenses | 125↑50.6% | 83↑129.6% | 36↑249.0% | 10 | |
| Operating Results | |||||
| Operating Income | -125↓50.6% | -83↓129.6% | -36↓249.0% | -10 | |
| Depreciation & Amortization | 1↑21.2% | 0.84↑649.1% | 0.11↑646.7% | 0.02 | |
| EBITDA | -124↓60.2% | -77↓123.5% | -35↓234.9% | -10 | |
| EBIT | -125↓59.8% | -78↓125.2% | -35↓235.4% | -10 | |
| Interest & Other Income | |||||
| Net Interest Income | 14↑12.2% | 12↑380.3% | 3↑986.7% | -0.29 | |
| Interest Income | 14↑12.2% | 12↑380.3% | 3 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.29 | |
| Non-Operating Income | 0.00↑100.0% | -5↓238.4% | -1 | 0.00 | |
| Other Income / Expenses | 14↑186.8% | 5↑238.4% | 1↑592.3% | -0.29 | |
| Income Before Tax | -111↓42.4% | -78↓125.2% | -35↓226.5% | -11 | |
| Income Tax Expense | 0.00 | 0.00↓100.0% | 0.01 | 0.00 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -111↓42.4% | -78↓125.1% | -35↓226.6% | -11 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -111↓42.4% | -78↓125.1% | -35↓226.6% | -11 | |
| Bottom-Line Net Income | -111↓42.4% | -78↓125.1% | -35↓226.6% | -11 | |
| EPS (Basic) | -2.86↑24.3% | -3.78↓297.9% | -0.95↓227.6% | -0.29 | |
| EPS (Diluted) | -2.86↑24.3% | -3.78↓297.9% | -0.95↓227.6% | -0.29 | |
| Weighted Average Shares | 47↑126.5% | 21↑14.7% | 18↓10.1% | 20 | |
| Weighted Average Diluted Shares | 47↑126.5% | 21↑14.7% | 18↓10.1% | 20 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.